Navigation Links
Trius to Present at San Diego Biotechnology Network Event
Date:10/22/2010

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that John Finn, Ph.D., Chief Scientific Officer at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; The Trius Therapeutics Story" at the San Diego Biotechnology Network event taking place on October 26, 2010 from 5:30-9:30 p.m. PT.

More information on the event is available at http://sdbn.org/october.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trius to Participate in Antibiotics Panel Discussion at Citis 5th Annual Biotech Day
2. Trius Therapeutics Reports 2010 Second Quarter Results
3. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
4. Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
5. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
6. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
7. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
8. Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010
9. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
10. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
11. SDForum and Innovation Center Denmark Present: The Future of Health Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
(Date:9/19/2014)... than electricity, to move data would consume much ... growing concern as chips, transistor counts rise. , ... light emitters, modulators, and detectors emitters ... source for optical chips is molybdenum disulfide (MoS2), ... a single, atom-thick layer. Other experimental on-chip light ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2
... Consolidated service revenue of $238.7 million grows 32% year-over-year, - ... - Backlog increases ... - Net quarterly book-to-burn ratio ... PRXL ) today announced its financial results for the,second quarter ...
... of Family Cord Blood Banks, LOS ANGELES, ... of California Cryobank, today announced that its co-founder ... appointed to the Department,of Health and Human Services, ... on Blood Stem Cell Transplantation,(ACBSCT). Through his appointment, ...
... required milestone for functional food partners and ... /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources Inc. ("Neptune") ... Oil ("NKO(R)") has been determined to be,safe ... status required for the,commercialization of NKO(R) incorporated ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 2Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 3Neptune Technologies receives GRAS notification in the United States 2Neptune Technologies receives GRAS notification in the United States 3
(Date:9/21/2014)... team of Stanford researchers has developed a protein therapy ... break away from original tumor sites, travel through the ... the body. , This process, known as metastasis, can ... "The majority of patients who succumb to cancer fall ... Cochran, an associate professor of bioengineering who describes a ...
(Date:9/19/2014)... study multifunctional and specialized spinal cord nerve cells ... Foundation grant in the amount of $680,000 for ... the Department of Biology, OU College of Arts ... the multifunctional and specialized spinal cord nerve cells ... connections they make. Berkowitz will collaborate with ...
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... motor excitability have a better working memory than humans with ... by scientists from the Transfacultary Research Platform at the University ... drawn as to the general cortical excitability as well ... temporary storage of information such as memorizing a phone number ...
... found new clues to how plants evolved to withstand wintry ... issue of the journal Nature , the team constructed ... plants the largest time-scaled evolutionary tree to date. By ... stem data for thousands of species, the researchers were able ...
... The Scripps Research Institute (TSRI) have demonstrated a drug-discovery ... of chemical compounds that have a desired effect on ... To illustrate the power of the innovative technique, the ... shows promise for treating obesity-linked diabetes. At the same ...
Cached Biology News:Motor excitability predicts working memory 2Study offers clues to how plants evolved to cope with cold 2Study offers clues to how plants evolved to cope with cold 3Innovative screening strategy swiftly uncovers new drug candidates, new biology 2Innovative screening strategy swiftly uncovers new drug candidates, new biology 3Innovative screening strategy swiftly uncovers new drug candidates, new biology 4
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
Biology Products: